64 results
8-K
EX-1.1
NKTX
Nkarta Inc
28 Mar 24
Other Events
4:08pm
would prevent the issuance or sale of the Securities; and no injunction, restraining order or order of any other nature by any federal or state court … of the nature contemplated by Sections 7(a) and 7(b) effected without its written consent if (i) such settlement is entered into more than forty-five
424B5
NKTX
Nkarta Inc
25 Mar 24
Prospectus supplement for primary offering
8:15pm
believe that the modular nature of our platform and the proprietary technologies we use for the multiplex engineering of NK cells, which include genome
8-K
EX-99.1
NKTX
Nkarta Inc
25 Mar 24
Regulation FD Disclosure
6:05am
autoimmune disease Tsokos, N Engl J Med 2011; 365:2110-2121. 1: Canaccord Genuity, 14 Nov 2023. 2: Mackensen et al. Nature Med. 28 Oct 22. 2124–2132 … . Autoimmune disease B cell malignancy Mackensen et al. Nature Med. 28 Oct 22. 2124–2132.
Immune “reset” occurs after B cell suppression in as short as 50
8-K
EX-99.1
NKTX
Nkarta Inc
8 Jan 24
Regulation FD Disclosure
8:50am
for patients with refractory autoimmune disease Tsokos, N Engl J Med 2011; 365:2110-2121. 1: Canaccord Genuity, 14 Nov 2023. 2: Mackensen et al. Nature … responses also retained, including to vaccines Mackensen et al. Nature Med. 28 Oct 22. 2124–2132.
Patient samples from ongoing NHL trial show
8-K
EX-99.1
2qnccizkxyf 6i5jc
11 May 23
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
4:06pm
S-3/A
iarq459t35doqyx36
24 Apr 23
Shelf registration (amended)
5:21pm
8-K
EX-99.1
ylr2 nvgmlyobejewond
9 Nov 22
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
4:03pm
8-K
EX-99.1
elaamk
11 Aug 22
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
4:10pm
8-K
EX-1.1
a2ign
28 Apr 22
Other Events
4:20pm
8-K
EX-99.1
x13qa0loq6xkvh
7 Oct 21
Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs
4:09pm
S-3
EX-4.7
1f0bl0gcnyf2xplj
12 Aug 21
Shelf registration
5:04pm